Cellectar Biosciences has named John Friend, M.D. as chief medical officer. He most recently served as senior vice president of medical and scientific affairs at Helsinn. Prior to his role at Helsinn, Dr. Friend held executive responsibility for clinical research, medical affairs, pharmacovigilance and risk management at various pharmaceutical companies, including Akros Pharma, Actavis, Alpharma, Hospira and Abbott.
Juno Therapeutics has hired Sunil Agarwal to lead the company’s research and development. Dr. Agarwal previously served as
chief medical officer and executive vice president at Ultragenyx. Prior to that role, he held several senior leadership positions at Genentech, most recently as senior vice president in charge of global development for ophthalmology, metabolism, neuroscience, immunology, and infectious diseases.
Bio-Path Holdings has appointed Dr. William Hahne as vice president of clinical development. Before joining Bio-Path, Dr. Hahne was a medical consultant for Voisin consulting, Medimmune, Lion Biotechnologies, Seattle Genetics, Aminex Therapeutics, Therakos and Celgene Cellular Therapeutics.